erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the.
.
following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv)..
..
.jeffrey krasner is president of emerging biocommunications, which consults to early- and mid-stage life science companies..
. it causes stroke and dementia as well as mood disturbance. svd increases with age but is accelerated by hypertension and diabetes.